Life Sciences INDUSTRIES

We represent industry leaders in biotechnology, pharmaceuticals, medical devices and beyond in confronting and resolving challenges in all aspects of the life sciences industry.


Recognized both globally and nationally as a leading life sciences practice, WilmerHale has represented life sciences clients in boardrooms and courtrooms across the United States and Europe for more than four decades. From biotechnology, pharmaceutical and medical device companies at all stages of growth to venture capitalists and investment banks, we understand the business of our life sciences clients and the changing regulatory, competitive and consumer demands that the industry faces. Our work in supporting life sciences clients has led to the group being named a "Practice Group of the Year" by Law360.

Many of our lawyers have advanced degrees in relevant scientific disciplines and more than 100 of our lawyers devote a significant portion of their practice to aspects critical to life sciences clients. Those aspects include corporate finance, licensing and alliances, mergers and acquisitions, patent prosecution and other intellectual property matters, patent and product liability. We also work with clients on securities, litigation and FDA, competition and other regulatory matters.

Contacts

Sort By
Der Marderosian, Lia

Lia Der Marderosian

Vice Chair, Corporate Practice Group

Co-Chair, Life Sciences Group

+1 617 526 6982 (t)

lia.dermarderosian@wilmerhale.com

Falber, Stuart M.

Stuart M. Falber

Co-Chair, Life Sciences Group

+1 617 526 6663 (t)

stuart.falber@wilmerhale.com

johnson-brian.jpg

Brian A. Johnson

Co-Chair, Capital Markets

+1 212 937 7206 (t)

brian.johnson@wilmerhale.com

Singer, Steven D.

Steven D. Singer

Chair, Transactional Department

+1 212 295 6307 (t)

steven.singer@wilmerhale.com

Experience

We have represented life sciences clients in venture financings, public offerings, mergers and acquisitions, licensing agreements and collaborations. We also have protected their innovations through patent prosecution and portfolio development; defended their interests in enterprise-critical patent litigation; and navigated regulatory issues vital to their success.

 Read about some of our recent life sciences transactions.

Clients

Our life sciences clients include:

  • Achillion
  • Agios Pharmaceuticals
  • Argos Therapeutics
  • AVEO Pharmaceuticals
  • Bristol-Myers Squibb
  • Cephalon
  • Cerulean Pharma
  • CoNCERT Pharmaceuticals
  • Cynosure
  • Curis
  • Durata Therapeutics
  • Eleven Biotherapeutics
  • Emergent BioSolutions
  • Epizyme
  • Idenix
  • Idera Pharmaceuticals
  • Infinity Pharmaceuticals
  • Karyopharm Therapeutics
  • The Medicines Company
  • Medtronic
  • Merrimack Pharmaceuticals
  • Novartis Pharmaceuticals Corporation
  • Ophthotech Corporation
  • Pacira Pharmaceuticals
  • PAREXEL
  • PerkinElmer
  • PTC Therapeutics
  • Tetraphase Pharmaceuticals
  • Thermo Fisher Scientific
  • uniQure biopharma

Publications & News

View

September 15, 2014

Delaware Court of Chancery Once Again Upholds Forum Selection Bylaw Requiring Intra-Corporate Litigation to Be Brought in a Forum Chosen by the Board of Directors

Once announced, merger and acquisition transactions typically result in the filing of numerous lawsuits in multiple jurisdictions. The Delaware Chancery Court has once again approved forum selection bylaw as a way to reduce the expense and distraction of multi-forum litigation.

September 1, 2014

Technical and Scientific Experience

Our ability to provide superior legal representation to technology companies is greatly enhanced by the academic and industry experience of our lawyers in a wide variety of technical and scientific fields.    

August 29, 2014

Q&A With WilmerHale’s Brian Johnson

A question and answer interview with Brian Johnson, published in Law360 on August 29, 2014.

August 28, 2014

LMG Life Sciences Honors Firm, Attorneys with Top Rankings for Third Consecutive Year

The 2014 edition of LMG Life Sciences has been released, and it includes the recognition of nine WilmerHale practice areas and 17 attorneys.

July 17, 2014

WilmerHale and 17 Partners Rank in Managing IP’s 2014-2015 IP Stars Handbook

Managing IP has released its second annual edition of its IP Stars Handbook—a guide that identifies the leading IP firms and lawyers in the United States—prominently ranking WilmerHale and 17 of its partners.

July 2, 2014

Nicox to Acquire Aciex Therapeutics, Inc.

Nicox S.A. today announced it has signed an agreement to acquire all of the outstanding equity of Aciex Therapeutics, Inc., a private, US-based, ophthalmic development pharmaceutical company with a strong near-term pipeline of therapeutics addressing major segments of the ophthalmic market, including allergy and inflammation.

May 23, 2014

Chambers USA Ranks Top WilmerHale Lawyers and Practices in 2014 Edition

We are pleased to announce the names of the individuals and practice areas that are ranked in the 2014 edition of Chambers USA: America's Leading Lawyers for Business.

May 20, 2014

Ophthotech Corporation Enters into Ex-US Licensing and Commercialization Agreement for Fovista® with Novartis

On May 19, 2014, WilmerHale client Ophthotech Corporation announced that the company had entered into an ex-US licensing and commercialization agreement with Novartis Pharmaceuticals focused on the treatment of wet age-related macular degeneration (AMD).

May 14, 2014

WilmerHale Named Among America’s Top Corporate Law Firms

WilmerHale has been named to NYSE Governance Services and FTI Consulting’s “America’s Top Corporate Law Firms,” a comprehensive ranking of the top 25 firms in the nation.

May 6, 2014

2014 Corporate Reports

WilmerHale’s annual IPO, Venture Capital and M&A Reports provide comprehensive statistics and analysis that are hard to find elsewhere.

Recognition

As a result of our skill and experience in the life sciences field, we have received many accolades, including:

  • Chambers USA: America's Leading Lawyers for Business 2007-2014 named WilmerHale a top law firm for life sciences with attorneys who are "consistently excellent people," "very responsive" and who "continue to stand out." WilmerHale is "a very strong firm" who is "in the top 1%" in the area of life sciences. 
  • Chambers Global 2013 and 2014 recognized WilmerHale as a leader in life sciences with an "outstanding US practice coupled with international reach."
  • Chambers Europe 2013 recognized WilmerHale as a leader in life sciences in Germany.
  • Law360 has named WilmerHale as a "Life Sciences Practice Group of the Year" for 2013 in its annual competition which recognizes five firms per practice area that have played a key role in the significant matters that made headlines and changed the legal landscape within the past year. This is the fourth consecutive year the firm has been named a "Practice Group of the Year" by Law360.
  • Legal 500 US 2013 ranked WilmerHale among the top law firms for life sciences. In the 2013 edition of the guidebook, a source stated that our firm "brings a great deal of experience to any situation" and says that our firm "has access to additional expertise/resources to help solve any problem."
  • LMG Life Sciences ranked the firm in their 2013 edition in the areas of patent prosecution, corporate, and licensing and collaboration. The firm was also named a "Lifecycle Firm," meaning the firm is regarded as one of the best full-service law firms within the life sciences industry.
  • LMG Life Sciences named WilmerHale the winner of the 2013 "Canadian Impact Deals of the Year" award. The firm was recognized for its representation of Enobia Pharma in the company's acquisition by Alexion Pharmaceuticals, Inc.
  • Managing IP recognized WilmerHale in 2013 as one of the best in the nation and named the firm "National Patent Contentious Firm of the Year" and "Pharmaceutical IP Litigation Firm of the Year."
  • Managing IP named WilmerHale among the top nationally ranked firms in their 2013-14 guide, and received a "Tier 1" ranking in the area of life sciences.
  • PLC Life Sciences Industry Super League 2012 named WilmerHale among the top ten law firms for having "a strong transatlantic life sciences practice."
  • PLC Cross-border Life Sciences Handbook 2011/12, 2009/10, 2008/09, 2007/08 and 2006/07 named WilmerHale a leading law firm in the area of life sciences.
  • The American Lawyer placed WilmerHale on their 2013 "A-List" as one of the nation's leading law firms. This is the tenth year the firm has received this recognition.
  • The American Lawyer recognized WilmerHale as its "IP Litigation Department of the Year" in 2014.
  • The National Law Journal named WilmerHale to the 2012 and 2013 Intellectual Property Hot Lists, which honors firms who demonstrate creative strategies for litigation, patent prosecution, licensing and other transactional work.
  • U.S. News – Best Lawyers® ranked the firm in their 2014 edition in the areas of intellectual property and corporate law, and awarded WilmerHale as a first-tier law firm in 27 national and 60 metro-area rankings.